Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings
AMLX·Reported May 8, 2025·Before market open
Diluted EPS came in at $-0.42 (+8.7% YoY), beat the $-0.45 consensus by $0.03.
Diluted EPS
$-0.42beat by $0.03
Consensus: $-0.45
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Amylyx Pharmaceuticals, Inc.'s Q1 2025 earnings report.
Amylyx Pharmaceuticals, Inc. (AMLX) reported Q1 2025 earnings on May 8, 2025 before market open.
Amylyx Pharmaceuticals, Inc. reported diluted EPS of $-0.42 for Q1 2025.
EPS beat the consensus estimate of $-0.45 by $0.03.
Compared to the same quarter a year prior, diluted EPS grew 8.7% from $-0.46.
You can read the 10-Q periodic report (0000950170-25-066363) directly on SEC EDGAR. The filing index links above go to sec.gov.